SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the amended applications upper-limb data. Many interpret recent rare-disease discussions and commercial-launch job postings as encouraging signs, while skeptics point to the prior FDA setback and question whether the evidence will be sufficient; approval remains uncertain.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios reported FDA approval of a competing RRP treatment has fueled debate over the threat to Precigens PAPZIMEOS and whether the selloff is an overreaction; traders disagree on the therapies relative advantages and Precigens commercial head start. Attention is also turning to upcoming PRGN-2009 clinical data and a Q3 business update.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Shares are climbing to a fresh 52-week high as traders position ahead of the expected Q3 report, with BRIUMVI sales growth supporting optimism. Some also speculate about a potential buyout or short squeeze, but the takeover chatter is unconfirmed, and others attribute the move to earnings expectations and momentum.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas announced addition to the S&P 500, replacing Kenvue, is drawing attention, with traders weighing index-related buying against a possible sell-the-news reaction. Some posts also raise unverified claims about a DHS-related breach, but they do not appear to be the main catalyst.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Golds sharp selloff, with GLD hitting a 52-week low, is tied in the discussion to inflation worries and expectations that interest rates may stay higher or rise. Traders debate whether gold has failed as a safe haven, while some see capitulation and a buying opportunity and others expect further losses.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff has traders focused on analyst price-target cuts and uncertainty around the upcoming earnings report, with weakness in advertising-related stocks adding to concerns. Bulls argue the decline is excessive given the companys profitability and growth, while bears worry about slowing ad demand and whether results or guidance will restore confidence.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp technology selloff, as traders debate whether worries about AI spending and returns, alongside weakness in chip stocks, signal a deeper correction. The community is split between expecting more downside and viewing the drop as an oversold buying opportunity, with late-session rebounds fueling debate over whether a bottom is forming.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers upcoming quarterly earnings report is the main focus, with traders watching whether results and guidance can support the recent rally. Sentiment is split between hopes for an earnings beat and renewed strength in big pharma, and concerns about the companys growth outlook and patent expirations.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for DefenCath could decline after early 2027 has fueled concerns about pricing and CorMedixs largest revenue driver. Traders are divided: some see the comments as a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMSs reimbursement estimate as a counterweight.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas early Baxfendy sales are prompting concern that aldosterone-synthase inhibitor drugs may ramp commercially more slowly than expected, weighing on MLYS despite no company-specific news behind the drop. Traders debate whether lorundrostat can overcome launch and competition risks, while some point to its upcoming FDA decision and clinical data as potential offsets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
